• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

U22 方案作为评估心房颤动导管消融术后症状改善的指标。

U22 protocol as measure of symptomatic improvement after catheter ablation of atrial fibrillation.

机构信息

Department of Cardiology, Heart Centre, University Hospital , S-901 85 Umeå , Sweden.

出版信息

Ups J Med Sci. 2013 Nov;118(4):240-6. doi: 10.3109/03009734.2013.821190.

DOI:10.3109/03009734.2013.821190
PMID:24102147
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4190885/
Abstract

INTRODUCTION

Left atrial catheter ablation is useful as symptomatic treatment in selected patients with atrial fibrillation (AF). Evaluation requires measurement of arrhythmia-related symptoms. Many of the published protocols have drawbacks and have been used in AF only, with no possible comparison to other ablations that compete for the same resources. U22 is a published protocol that quantifies paroxysmal tachycardia symptoms through scales with 11 answer alternatives, translated into discrete numerical scales 0-10. It has been shown to reflect the clinical improvement after ablation of supraventricular tachycardia. Here we report the use of U22 in measuring improvement after catheter ablation for AF.

MATERIAL AND METHODS

A total of 105 patients underwent first-time ablation for AF and answered U22 and SF-36 forms at baseline and follow-up 304 (SD 121) days after ablation. Independently, the patients underwent a clinical follow-up. All decisions regarding medication and reablation were taken without knowledge of the symptom scores. Results. The U22 scores for well-being, arrhythmia as cause for impaired well-being, derived time-aspect score for arrhythmia, and discomfort during attack detected relevant improvements of symptoms after the ablation. U22 showed larger improvement in patients undergoing only one procedure than in patients who later underwent repeated interventions, thus reflecting the independent clinical decision for reablation.

CONCLUSION

U22 quantifies the symptomatic improvement after AF ablation with adequate internal consistency and construct validity. U22 mirrors aspects of the arrhythmia symptomatology other than SF-36.

摘要

简介

左心房导管消融术对于有症状的心房颤动(AF)患者是一种有效的治疗方法。评估需要测量与心律失常相关的症状。许多已发表的方案都有缺点,仅在 AF 中使用,无法与其他竞争相同资源的消融术进行比较。U22 是一种已发表的方案,通过具有 11 个答案选择的量表来量化阵发性心动过速症状,转化为离散的数值量表 0-10。它已被证明能反映出对室上性心动过速消融后的临床改善。在这里,我们报告了 U22 在测量 AF 导管消融后改善情况中的应用。

材料和方法

共有 105 例患者首次接受 AF 消融治疗,并在消融后 304 天(SD 121)时进行 U22 和 SF-36 问卷调查。独立地,患者接受了临床随访。所有关于药物治疗和再消融的决定都是在不知道症状评分的情况下做出的。结果:U22 在健康状况、心律失常作为健康状况受损的原因、心律失常的衍生时间方面评分以及发作时的不适方面的评分显示出了症状改善。与后来接受重复干预的患者相比,仅接受一次手术的患者 U22 评分的改善更大,这反映了再消融的独立临床决策。

结论

U22 以足够的内部一致性和结构有效性量化了 AF 消融后的症状改善。U22 反映了 SF-36 以外的心律失常症状学方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29dd/4190885/7e9fcb1e97b0/UPS-118-240-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29dd/4190885/ffb918f7c80c/UPS-118-240-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29dd/4190885/7e9fcb1e97b0/UPS-118-240-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29dd/4190885/ffb918f7c80c/UPS-118-240-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29dd/4190885/7e9fcb1e97b0/UPS-118-240-g002.jpg

相似文献

1
U22 protocol as measure of symptomatic improvement after catheter ablation of atrial fibrillation.U22 方案作为评估心房颤动导管消融术后症状改善的指标。
Ups J Med Sci. 2013 Nov;118(4):240-6. doi: 10.3109/03009734.2013.821190.
2
Symptomatic improvement after catheter ablation of supraventricular tachycardia measured by the arrhythmia-specific questionnaire U22.心律失常问卷 U22 测量的室上性心动过速导管消融后的症状改善。
Ups J Med Sci. 2011 Mar;116(1):52-9. doi: 10.3109/03009734.2010.517875. Epub 2010 Nov 16.
3
U22, a protocol to quantify symptoms associated with supraventricular tachycardia.U22,一种用于量化与室上性心动过速相关症状的方案。
Pacing Clin Electrophysiol. 2009 Mar;32 Suppl 1:S105-8. doi: 10.1111/j.1540-8159.2008.02263.x.
4
Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation.阵发性心房颤动的左右心房射频导管治疗
J Cardiovasc Electrophysiol. 1996 Dec;7(12):1132-44. doi: 10.1111/j.1540-8167.1996.tb00492.x.
5
Predictors of improvement in arrhythmia-specific symptoms and health-related quality of life after catheter ablation of atrial fibrillation.房颤导管消融术后心律失常特异性症状及健康相关生活质量改善的预测因素。
Clin Cardiol. 2019 Feb;42(2):247-255. doi: 10.1002/clc.23134. Epub 2018 Dec 21.
6
Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation.代谢综合征对接受导管消融治疗的心房颤动患者手术结果的影响。
J Am Coll Cardiol. 2012 Apr 3;59(14):1295-301. doi: 10.1016/j.jacc.2011.11.051.
7
Impact of Radiofrequency Ablation and Antiarrhythmic Medications on the Quality of Life of Patients with Supraventricular Tachycardias: Preliminary Validation of the Greek Version of the Umea22 (U22) Questionnaire.射频消融术和抗心律失常药物对室上性心动过速患者生活质量的影响:乌默奥 22(U22)问卷希腊语版本的初步验证。
Biomed Res Int. 2018 Oct 9;2018:3059478. doi: 10.1155/2018/3059478. eCollection 2018.
8
Safety and efficacy of early radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation complicated with amiodarone-induced thyrotoxicosis.早期射频导管消融治疗阵发性心房颤动合并胺碘酮所致甲状腺毒症患者的安全性和有效性
Cardiol J. 2016;23(4):416-21. doi: 10.5603/CJ.a2016.0029. Epub 2016 Jun 14.
9
Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial.射频消融与抗心律失常药物作为阵发性心房颤动(RAAFT-2)一线治疗的比较:一项随机试验。
JAMA. 2014 Feb 19;311(7):692-700. doi: 10.1001/jama.2014.467.
10
Long-term clinical outcome of patients who failed catheter ablation of atrial fibrillation.心房颤动导管消融失败患者的长期临床结局
Europace. 2015 Mar;17(3):403-8. doi: 10.1093/europace/euu229. Epub 2014 Oct 21.

引用本文的文献

1
Radiofrequency Catheter Ablation Improves the Quality of Life Measured with a Short Form-36 Questionnaire in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis.射频导管消融术改善房颤患者基于简明健康状况调查量表-36的生活质量:一项系统评价和荟萃分析
PLoS One. 2016 Sep 28;11(9):e0163755. doi: 10.1371/journal.pone.0163755. eCollection 2016.

本文引用的文献

1
Development and validation of a new Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmia (ASTA) with focus on symptom burden.开发并验证了一个新的心律失常特异性问卷——心动过速和心律失常(ASTA),该问卷侧重于症状负担。
Health Qual Life Outcomes. 2012 Apr 30;10:44. doi: 10.1186/1477-7525-10-44.
2
Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation.心房颤动对生活质量影响问卷(AFEQT)在心房颤动患者中的开发和验证。
Circ Arrhythm Electrophysiol. 2011 Feb;4(1):15-25. doi: 10.1161/CIRCEP.110.958033. Epub 2010 Dec 15.
3
Symptomatic improvement after catheter ablation of supraventricular tachycardia measured by the arrhythmia-specific questionnaire U22.
心律失常问卷 U22 测量的室上性心动过速导管消融后的症状改善。
Ups J Med Sci. 2011 Mar;116(1):52-9. doi: 10.3109/03009734.2010.517875. Epub 2010 Nov 16.
4
Validation of the AF-QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation.验证 AF-QoL,一种用于心房颤动患者的特定疾病生活质量问卷。
Europace. 2010 Mar;12(3):364-70. doi: 10.1093/europace/eup421. Epub 2010 Jan 6.
5
Validity and reliability of a new, short symptom rating scale in patients with persistent atrial fibrillation.一种新型简短症状评定量表在持续性心房颤动患者中的效度和信度
Health Qual Life Outcomes. 2009 Jul 15;7:65. doi: 10.1186/1477-7525-7-65.
6
Validating a new quality of life questionnaire for atrial fibrillation patients.验证一种新的用于房颤患者的生活质量问卷。
Int J Cardiol. 2010 Sep 3;143(3):391-8. doi: 10.1016/j.ijcard.2009.03.087. Epub 2009 Apr 24.
7
U22, a protocol to quantify symptoms associated with supraventricular tachycardia.U22,一种用于量化与室上性心动过速相关症状的方案。
Pacing Clin Electrophysiol. 2009 Mar;32 Suppl 1:S105-8. doi: 10.1111/j.1540-8159.2008.02263.x.
8
Sustained high quality of life in a 5-year long term follow-up after successful ablation for supra-ventricular tachycardia. results from a large retrospective patient cohort.室上性心动过速成功消融术后5年长期随访中的持续高质量生活。来自大型回顾性患者队列的结果。
Int J Med Sci. 2009;6(1):28-36. doi: 10.7150/ijms.6.28. Epub 2009 Jan 11.
9
Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association.心房颤动试验的结果参数:德国心房颤动能力网络和欧洲心律协会组织的共识会议的建议。
Europace. 2007 Nov;9(11):1006-23. doi: 10.1093/europace/eum191. Epub 2007 Sep 25.
10
A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: the CCS-SAF scale.一种用于在床边评估房颤症状严重程度的新型简易量表:CCS-SAF量表。
Can J Cardiol. 2006 Apr;22(5):383-6. doi: 10.1016/s0828-282x(06)70922-9.